MyChesCo on MSN
Medicus submits phase 2 study design for Teverelix to FDA
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results